Researchers identified three new sRNA named ErsA, ReaL and PesA. They have shown that these three sRNA are widespread among P. aeruginosa clinical isolates from CF patients and environmental strains. The main goal of the project was achieved monitoring the secretion of the proinflammatory interleukin IL-8 and cell viability following infection of a CF bronchial epithelial cell line with P. aeruginosa wild type (wt) and sRNA knock-out mutants strains. The sRNA mutants showed to be less proinflammatory than the wt inducing a lower production of IL-8. In addition the sRNA mutants induced lower cell death of infected bronchial epithelial cells. Drug molecules that can bind and inhibit sRNA functions have the potential to foster the development of innovative antimicrobial strategies. In addition, due to their specificity these drugs would preserve CF patient healty commensal flora.